lifestyle.brownplanet.com

Author: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

May 5, 2026
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference

May 5, 2026
Mineralys Therapeutics to Announce First Quarter 2026 Financial Results and Host Conference Call on Wednesday, May 6, 2026

April 29, 2026
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

March 24, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

March 16, 2026
Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

March 14, 2026
Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

March 13, 2026
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on Thursday, March 12, 2026

March 13, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

March 12, 2026
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

March 10, 2026